Funding of abiraterone and other products supplied by Janssen

This decision is expected to result in up to 1000 men with advanced prostate cancer receiving funded abiraterone per year.

Funding of abiraterone and other products supplied by Janssen. PHARMAC is pleased to announce the approval of a proposal for abiraterone acetate (Zytiga) ...

ZYTIGA® Patient Assistance | ZYTIGA® (abiraterone acetate)

Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year ...

Affordability Support: Janssen CarePath Savings Program

Your eligible patients will pay $10 per month with a $12,000 maximum program benefit per calendar year or one-year supply, whichever comes first. Not valid for ...

Fiscal Third Quarter Ended June 30, 2023 - SEC.gov

In April 2023, the Company entered into a clinical trial support agreement with Janssen Research & Development, LLC (“Janssen”) under which ...

Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib ...

D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. “It also demonstrates our ongoing commitment at Janssen to ...

Disparity in public funding of therapies for metastatic castrate ...

Both androgen receptor-axis-targeted therapies (ARATs), abiraterone acetate plus prednisone and enzalutamide, are funded by provinces in the pre-and post- ...

Abiraterone for Prostate Cancer Not Previously Treated with ...

MRC provided funding for the trial through core funding to UCL. Cancer Research U.K. approved the trial design and subsequent amendments and ...

U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate ...

“Janssen's legacy of advancing the science of prostate cancer has contributed to the evolution of transformational treatment approaches for more ...

Federal Court of Appeal upholds obviousness finding re: Janssen's ...

Trial judge's finding that abiraterone acetate was known to be a prostate cancer treatment · Identifying and applying the gap between the state ...

AstraZeneca enters co-promotion agreement with Janssen in Japan ...

AstraZeneca today announced that it has entered into an agreement with Janssen Pharmaceuticals KK in Japan to co-promote abiraterone acetate.

Helping Patients Afford ZYTIGA - Janssen CarePath

ZYTIGA® (abiraterone acetate) is indicated in combination with prednisone for the treatment of patients with:.

The high cost of publicly funded cancer drugs - The Conversation

The U-turn comes after a lower price was agreed with the manufacturer Janssen – making abiraterone affordable for widespread use. Janssen is ...

Apalutamide plus abiraterone acetate and prednisone in metastatic ...

Funding. Funded by Janssen Research & Development. Introduction. Progression to metastatic castration-resistant prostate cancer (mCRPC) occurs ...

Janssen Announces U.S. FDA Breakthrough Therapy Designation ...

Niraparib is currently marketed as ZEJULA® by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to ...

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive ...

All the patients provided written informed consent. An independent data and safety monitoring committee was commissioned by the sponsor, Janssen ...

Abiraterone for Hormone-Sensitive Prostate Cancers - NCI

LATITUDE was funded in full and STAMPEDE in part by Janssen Research and Development, the manufacturer of abiraterone. LATITUDE included ...

Fiscal Second Quarter Ended March 31, 2023 - SEC.gov

In April 2023, the Company entered into a clinical trial support agreement with Janssen Research & Development, LLC (“Janssen”) under which ...

Case 2:19-cv-14146-KM-JBC Document 83 Filed 08/05/19 Page 1 ...

During the time that the '213 patent was in place, only Janssen could sell an abiraterone acetate product; no other company could. On April 28, ...

Abiraterone: a story of scientific innovation and commercial ...

In May 2012, NICE and Janssen finally reached an agreement over cost, and the drug was made available on the NHS in England, Wales and Northern ...